## Express Mail Mailing Label No. EV631056275US Sheet 1 of

COURTESY FORM PTO – 1449				ATTORNEY DOCKET NO.: MEE-002								
SUPPLEMENTAL INFORMATION DISCLOSURE				APPLICANTS: Miller et al.								
STATEMENT 61PE				SERIAL NO.: 09/780,142								
SEP 1 9 2005 (m)				FILING DATE: February 9, 2001								
	B			:	EXAMINER: Huynh, P. GROUP: 1644							
		3 TRADENDA	U.S	S. PATENT D								
EXAM.		DOCUMENT	DATE	NAME		· · · · · · · · · · · · · · · · · · ·	CLASS	su	В	FILING	G DATE IF	
INIT.		NUMBER						CLASS		APPROPRIATE		
										<u></u>	•	
						<u></u>						
						, .						
			FORE	IGN PATENT	DOCUME!	NTS			<del></del>			
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLAS	S DAT		ABST	TRACT Y	ENGLISH LANG (Y/N)	
										•		
								11				
			OTHER A	RT, JOURNA	L ARTICLE	S, ETC	•					
EXAM. INIT.	ОТНЕ	R DOCUMENTS:	(Including A	uthor, Title, I	ate, Relevar	t Pages	s, Place of	Publi	cation)			
Phy	C133	Gauthier et al., "Safety and Efficacy of Intravitreal Injection of rhuFab V2, an Anti-vascular Endothelial Growth Factor (VEGF) Antibody Fragment, in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization," ARVO Poster, May 2002.										
N .	C134	Gauthier et al., "Safety and Efficacy of Intravitreal Injection of rhuFab VEGF in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization," ARVO. The Association for Research in Vision and Ophthalmology (Oasis, Online Abstract Submission and Invention System, Program Planner, Presentation # 566), May 2002.										
V	C138	Heier et al., "rhuFAB V2 (an Anti-VEGF Antibody Fragment) in Neovascular AMD: Safety and Tolerability of Multiple Intravitreal Injections - Preliminary Data from a Single Center," ARVO Poster, May 2002.										
	:		<u></u>						•••		<u></u>	
	<u> </u>						·		1			
EXAMINER DATE CONSIDERED 3/13/06												
LIBC/25760	)26.1											

Sheet Lof

FORM PTO – 1449				ATTORNEY DOCKET NO.: MEE-002								
SUPPLEMENTAL INFORMATION DISCLOSURE				APPLICANTS: Miller et al.  SERIAL NO.: 09/780,142  FILING DATE: February 9, 2001								
SEP 1 9 2005												
												EXAMINER: Huynh, P. GROUP: 1644
						RIO	EMARK	U.S	S. PATENT D	OCUMENTS	S	
EXAM. INIT.	DOCUMENT DATE NAME NUMBER		NAME		CLASS	SUB CLASS		FILING DATE IF APPROPRIATE				
Trust	A14	5,171,749	12/15/92	Levy et al.	vy et al.		514	410		06/20/91		
1	A15	6,162,242	12/19/00	Peyman			607	88		01/21/99		
	A16	6,899,723	05/31/05	Chen			607	88		07/13	/01	
	A17	2003-0175282	09/18/03	Miller et al	al.		424	133 05/		05/05	05/05/03	
1	A18	2003-0185834	10/02/03	Miller et al				133 05/05		05/05	/03	
			FORE	IGN PATENT	DOCUMEN	vts		<u>.                                    </u>				
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY	CLASS SUB			FILING ABST DATE ONLY		RACT '	ENGLISH LANG (Y/N)	
								·····				
			OTHER A	RT, JOURNA	I. ARTICLE	S ETC						
EXAM. INIT.	ОТНЕ	R DOCUMENTS:		•			, Place of l	Public	cation)			
Prilit	C170 Blaauwgeers et al., "Polarized Vascular Endothelial Growth Factor Secretion by Human Retinal Pigment Epithelium and Localization of Vascular Endothelial Growth Factor Receptors on the Inner Choriocapillaris," Am. J. Pathology 155(2): 421-428, 1999.											
	C171											
<b>V</b>	C172 Witte et al., "Monoclonal antibodies targeting the VEGF receptor-2 (Flk/KDR) as an anti- angiogenic therapeutic strategy," Cancer and Metastasis Reviews 17: 155-161, 1998.											
EXAMINE	<u></u>	D1 8. 74	- Andrew Williams		DATE CO				1			